CIBC Asset Management Inc Buys 525,025 Shares of Pfizer Inc. $PFE

CIBC Asset Management Inc grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 49.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,585,657 shares of the biopharmaceutical company’s stock after acquiring an additional 525,025 shares during the quarter. CIBC Asset Management Inc’s holdings in Pfizer were worth $39,483,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Brighton Jones LLC raised its position in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its position in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the period. United Bank raised its position in shares of Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares during the period. Sei Investments Co. raised its position in shares of Pfizer by 31.5% during the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after purchasing an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC raised its position in shares of Pfizer by 45.3% during the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after purchasing an additional 31,896 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.7%

PFE stock opened at $25.37 on Thursday. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The business has a 50 day moving average price of $26.68 and a two-hundred day moving average price of $26.29. The company has a market cap of $144.57 billion, a price-to-earnings ratio of 19.36 and a beta of 0.34. Pfizer Inc. has a twelve month low of $23.08 and a twelve month high of $28.75.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business’s revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s oncology pipeline drew renewed optimism after ASCO 2026 data showed encouraging Phase 3 results for BRAFTOVI in metastatic colorectal cancer and TALZENNA in prostate cancer, reinforcing the company’s long-term growth story. Pfizer Oncology Data At ASCO 2026 Reshapes Long Term Growth Story
• Positive Sentiment: Jefferies reiterated a buy rating on Pfizer, and another report highlighted Pfizer as undervalued, which may help support sentiment around the stock’s current valuation. Jefferies Reaffirms Their Buy Rating on Pfizer (PFE)
• Positive Sentiment: Pfizer also received coverage suggesting its obesity and oncology pipeline could deliver multiple catalysts in 2026, keeping investors focused on upcoming data readouts and regulatory events. Pfizer’s Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026
• Neutral Sentiment: Pfizer presented at the Jefferies Global Healthcare Conference, but the transcript appears to be mainly a routine investor update rather than a major new announcement. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Pfizer also announced updates on its ODEN ulcerative colitis study and completed a bevacizumab biosimilar safety study in Japan, both of which are incremental pipeline updates rather than immediate stock-moving breakthroughs. Pfizer’s ODEN Study Update: Real-World Data on Tofacitinib in Ulcerative Colitis
• Negative Sentiment: Some articles continue to frame Pfizer as a high-yield stock facing patent-cliff concerns and competitive comparisons with peers like Bristol Myers and Merck, which may weigh on sentiment despite the company’s pipeline progress. Bristol Myers vs. Pfizer: Which High-Yield Dividend Stock Wins Now?

Analysts Set New Price Targets

A number of equities research analysts have recently commented on PFE shares. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Pfizer in a research report on Monday. UBS Group reissued a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. Bank of America dropped their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Royal Bank Of Canada reissued an “underperform” rating and issued a $25.00 target price on shares of Pfizer in a research report on Monday, April 20th. Finally, Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a research report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.82.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.